Etiracetam is a nootropic agent. (-)-(S) enantiomer of etiracetam levetiracetam (Keppra®) is used for the treatment of epilepsy.

Guanclofine was studied as an adrenergic neuron blocking agent.

AstraZeneca R&D Charnwood (formerly Astra Charnwood, a subsidiary of AstraZeneca) was developing sibenadet (Viozan, AR-C68397AA) for the potential treatment of chronic obstructive pulmonary disease and asthma. Sibenadet is a dual D2 dopamine receptor, beta2-adrenoceptor agonist that combines bronchodilator activity with the sensory afferent modulating effects associated with D2-receptor agonism. Development of sibenadet has been discontinued due to disappointing efficacy findings.

Eplivanserin (SR 46349) is an antagonist of serotonin 2A receptor. Eplivanserin was previously in development by Sanofi-aventis in an effort to educate the public regarding this new mechanism of action for sleep aids. Eplivanserin was reviewed by the FDA as a potential treatment for patients with chronic insomnia, but the FDA requested additional information regarding benefit-risk and development of the drug has been discontinued.

Pafenolol is a beta 1 selective adrenoceptor blocker that was studied in phase I clinical trial in Sweden for the treatment of arrhythmia. However, this study was discontinued.

Morforex is phenylethylamine derivative that acts as central nervous system (CNS) and motor activity stimulant. Morforex produces amphetamine as an active metabolite.

Oletimol was developed as an antirheumatic agent that has never been marketed. Information about the current use of this drug is not available.